Positive News Sentiment NASDAQ:THRX Theseus Pharmaceuticals - THRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Theseus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $13.99 +1.38 (+10.94%) (As of 01/31/2023 05:19 PM ET) Add Compare Share Share Today's Range$11.90▼$14.2150-Day Range$4.96▼$12.6152-Week Range$4.01▼$15.21Volume441,005 shsAverage Volume529,975 shsMarket Capitalization$541.55 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Theseus Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside57.3% Upside$22.00 Price TargetShort InterestHealthy7.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1.01 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.42) to ($1.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsMedical Sector150th out of 1,055 stocksPharmaceutical Preparations Industry64th out of 518 stocks 3.5 Analyst's Opinion Consensus RatingTheseus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, Theseus Pharmaceuticals has a forecasted upside of 57.3% from its current price of $13.99.Amount of Analyst CoverageTheseus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.24% of the float of Theseus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTheseus Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Theseus Pharmaceuticals has recently decreased by 3.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTheseus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTheseus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for THRX. Previous Next 4.4 News and Social Media Coverage News SentimentTheseus Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Theseus Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest18 people have searched for THRX on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.MarketBeat Follows5 people have added Theseus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theseus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,010,323.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders49.00% of the stock of Theseus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.22% of the stock of Theseus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Theseus Pharmaceuticals are expected to decrease in the coming year, from ($1.42) to ($1.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theseus Pharmaceuticals is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theseus Pharmaceuticals is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheseus Pharmaceuticals has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Theseus Pharmaceuticals (NASDAQ:THRX) StockTheseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More Receive THRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address THRX Stock News HeadlinesJanuary 31, 2023 | seekingalpha.comTheseus Pharmaceuticals: Reinventing TKIs - I'd Buy The Next DipJanuary 5, 2023 | finance.yahoo.comTheseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development ProgramJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 15, 2022 | finance.yahoo.comInvesting in These 2 Biotech Stocks Could Double Your Money, Says AnalystNovember 23, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn SituationNovember 10, 2022 | benzinga.comTheseus Pharmaceuticals Director Makes $1.00M Stock PurchaseNovember 10, 2022 | benzinga.comBoard Member of Theseus Pharmaceuticals Makes $1.00M BuyNovember 3, 2022 | finance.yahoo.comTheseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial ResultsJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…October 26, 2022 | finance.yahoo.comTheseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR SymposiumOctober 19, 2022 | finance.yahoo.comTheseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of DirectorsOctober 3, 2022 | finance.yahoo.comTheseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung CancerSeptember 6, 2022 | finance.yahoo.comTheseus Pharmaceuticals to Participate at Upcoming September Investor ConferencesSeptember 4, 2022 | reuters.comTheseus Pharmaceuticals IncAugust 3, 2022 | finance.yahoo.comTheseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare ConferenceJuly 14, 2022 | uk.finance.yahoo.comTheseus Pharmaceuticals, Inc. (THRX)July 1, 2022 | finance.yahoo.comHC Wainwright Sees Over 300% Upside In This Cancer-Focused StockJune 30, 2022 | seekingalpha.comTheseus Pharmaceuticals initiated with a Buy at H.C. WainwrightMay 19, 2022 | finance.yahoo.comTheseus Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 18, 2022 | finance.yahoo.comTheseus Pharmaceuticals Appoints Don Hayden to Board of DirectorsMay 13, 2022 | seekingalpha.comTheseus Pharmaceuticals declares $0.46 dividendMay 12, 2022 | finance.yahoo.comTheseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial ResultsApril 8, 2022 | finance.yahoo.comTheseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual MeetingApril 7, 2022 | bizjournals.comClinical trial revisitedApril 5, 2022 | finance.yahoo.comTheseus Pharmaceuticals to Participate Virtually in Needham Healthcare ConferenceMarch 10, 2022 | seekingalpha.comTheseus Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04March 10, 2022 | finance.yahoo.comTheseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive THRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address THRX Company Calendar Last Earnings11/03/2022Today1/31/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:THRX CUSIPN/A CIK1745020 Webtheseusrx.com Phone857-400-9491FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.00 High Stock Price Forecast$22.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+57.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-19.55% Return on Assets-18.84% Debt Debt-to-Equity RatioN/A Current Ratio27.54 Quick Ratio27.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book2.20Miscellaneous Outstanding Shares38,710,000Free Float19,744,000Market Cap$541.55 million OptionableNot Optionable Beta2.09 Key ExecutivesDr. Iain D. Dukes D.Phil. (Age 64)DPHIL, M.A., Co-Founder & Chairman Comp: $289.49kDr. Timothy P. Clackson Ph.D. (Age 57)CEO, Pres & Director Comp: $691.84kDr. William C. Shakespeare Ph.D. (Age 59)Co-Founder and Pres of R&D Comp: $640.59kMr. Bradford D. Dahms (Age 33)Chief Financial officer Comp: $480.95kDr. Victor M. Rivera Ph.D. (Age 58)Co-Founder, Sr. VP & Chief Scientific Officer Mr. Wei-Sheng Huang Ph.D.Co-Founder & VP of ChemistryMr. Benjamin D. EnersonVP of Legal AffairsDr. David P. Kerstein M.D. (Age 40)Chief Medical Officer Dr. Nachu Narasimhan Ph.D.Sr. VP of Drug Metabolism & Preclinical SafetyMr. Len RozamusSr. VP of Technical OperationsMore ExecutivesKey CompetitorsPhathom PharmaceuticalsNASDAQ:PHATNektar TherapeuticsNASDAQ:NKTREntrada TherapeuticsNASDAQ:TRDACOMPASS PathwaysNASDAQ:CMPSVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 4,333 shares on 12/8/2022Ownership: 0.111%Bradford D DahmsBought 1,502 shares on 11/30/2022Total: $10,003.32 ($6.66/share)BNP Paribas Arbitrage SNCBought 15,310 shares on 11/16/2022Ownership: 0.040%Price T Rowe Associates Inc. MDSold 3,794 shares on 11/15/2022Ownership: 3.569%Vanguard Group Inc.Sold 3,371 shares on 11/15/2022Ownership: 1.617%View All Insider TransactionsView All Institutional Transactions THRX Stock - Frequently Asked Questions Should I buy or sell Theseus Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theseus Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" THRX shares. View THRX analyst ratings or view top-rated stocks. What is Theseus Pharmaceuticals' stock price forecast for 2023? 3 brokerages have issued 12 month price objectives for Theseus Pharmaceuticals' stock. Their THRX share price forecasts range from $22.00 to $22.00. On average, they expect the company's share price to reach $22.00 in the next year. This suggests a possible upside of 65.8% from the stock's current price. View analysts price targets for THRX or view top-rated stocks among Wall Street analysts. How have THRX shares performed in 2023? Theseus Pharmaceuticals' stock was trading at $4.98 at the beginning of the year. Since then, THRX stock has increased by 166.5% and is now trading at $13.27. View the best growth stocks for 2023 here. When is Theseus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our THRX earnings forecast. How were Theseus Pharmaceuticals' earnings last quarter? Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) issued its earnings results on Thursday, November, 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.04. When did Theseus Pharmaceuticals IPO? (THRX) raised $150 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 10,000,200 shares at $14.00-$16.00 per share. What is Theseus Pharmaceuticals' stock symbol? Theseus Pharmaceuticals trades on the NASDAQ under the ticker symbol "THRX." How do I buy shares of Theseus Pharmaceuticals? Shares of THRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Theseus Pharmaceuticals' stock price today? One share of THRX stock can currently be purchased for approximately $13.27. How much money does Theseus Pharmaceuticals make? Theseus Pharmaceuticals (NASDAQ:THRX) has a market capitalization of $513.68 million. The company earns $-27,310,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. How can I contact Theseus Pharmaceuticals? The official website for the company is theseusrx.com. The company can be reached via phone at 857-400-9491 or via email at christen.baglaneas@theseusrx.com. This page (NASDAQ:THRX) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.